Chronic obstructive pulmonary disease (COPD) progression has been linked to smoking-induced cellular senescence. Impaired autophagy and lysosomal dysfunction contribute to accumulation of damaged organelles and senescent phenotypes in lung epithelial cells. Transcription factor EB (TFEB) is a master regulator of the autophagy-lysosome axis and thus represents a therapeutic target to restore cellular proteostasis and organelle turnover.
This study evaluated pemafibrate, a clinically available fibrate and putative TFEB inducer, for senotherapeutic activity in COPD-relevant models. The authors tested pemafibrate in human bronchial epithelial cells exposed to cigarette smoke (CS) extract, in a long-term CS-exposed mouse model, and in a retrospective clinical cohort comparing pemafibrate with other fibrates.
Primary human bronchial epithelial cells and COPD lung epithelial cells were analyzed for TFEB expression and functional responses to CS extract and pemafibrate. The investigators report reduced TFEB expression in COPD lung epithelial cells compared with controls. Exposure to cigarette smoke extract impaired lysosomal acidification and autophagy/mitophagy flux, contributing to cellular senescence.
Treatment with pemafibrate enhanced autophagy and mitophagy flux in bronchial epithelial cells exposed to CS extract, and restored lysosomal acidification that had been disrupted by CS. These pemafibrate-induced changes were associated with a reduction in markers of cellular senescence in the treated epithelial cells.
To probe mechanism, TFEB knockdown experiments were performed. The authors report that suppression of TFEB attenuated the pemafibrate-induced improvements in autophagy/mitophagy flux, lysosomal acidification, and the reduction in cellular senescence. These results support a mechanistic role for TFEB induction in the cellular effects of pemafibrate observed in vitro.
The team used a long-term CS-exposed mouse model to examine pemafibrate’s effects in vivo. Pemafibrate administration increased TFEB expression in mouse lungs, mitigated alveolar enlargement, and reduced airflow obstruction relative to CS-exposed controls. The drug also attenuated the CS-induced increase in static lung compliance reported in this model.
The authors interpret these histologic and physiologic improvements as consistent with reduced smoking-induced lung injury and senescence, potentially mediated by restoration of autophagy/mitophagy and lysosomal function through TFEB upregulation.
Bulk RNA sequencing of lungs from the CS-exposed mice was performed to explore gene-expression changes associated with pemafibrate treatment. The authors report that RNA-seq results are consistent with attenuation of CS-induced cellular senescence and suggest involvement of autophagy/mitophagy-related pathways. Raw and processed RNA-seq data are being deposited in the NCBI Gene Expression Omnibus; the accession number will be provided upon revision of the preprint.
A retrospective cohort study was conducted to explore potential clinical associations between pemafibrate use and lung-function decline. The authors report that patients prescribed pemafibrate showed an attenuated decline in FEV1.0 compared with patients prescribed bezafibrate or fenofibrate. Detailed cohort selection criteria, numerical outcome measures, and statistical analyses are reported in the source article and should be consulted there for quantitative interpretation.
Ethical approval for use of human lung tissues and for the retrospective cohort study was provided by The Jikei University School of Medicine Ethics Committee. Written informed consent was obtained from participants who contributed surgical tissue; the requirement for informed consent was waived for the retrospective cohort in accordance with institutional guidelines, and an opt-out notice was posted on the hospital website. Clinical data were anonymized.
Pemafibrate used in the study was provided by Kowa Company, Ltd. One author declared receipt of support from a collaborative research fund from Kowa Company, Ltd.; the company had no role in study design, data collection, analysis, interpretation, abstract writing, or the decision to present results. The other authors declared no conflicts of interest. Funding sources reported include multiple grants and institutional research funds as detailed in the source article.
The combined preclinical and retrospective clinical observations reported by the authors indicate that pemafibrate may act as a senotherapeutic in COPD by inducing TFEB and restoring autophagy/mitophagy and lysosomal function. Pemafibrate reduced CS-induced cellular senescence in bronchial epithelial cells, mitigated emphysematous changes and lung-function impairment in a long-term CS mouse model, and was associated with less FEV1.0 decline in a retrospective human cohort compared with other fibrates.
These findings support further investigation of pemafibrate as a therapeutic candidate for COPD. The source article provides experimental and cohort details, while raw RNA-seq data are being deposited for public access. Specific quantitative outcomes, statistical metrics, long-term safety, and prospective clinical trial data were not reported in this summary and should be referenced directly from the full preprint for detailed evaluation.